{"id":"darolutamide-continuous","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4297185","moleculeType":"Small molecule","molecularWeight":"398.85"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Darolutamide competitively binds to the androgen receptor with high affinity and selectivity, preventing activation by testosterone and dihydrotestosterone. This blocks the transcription of androgen-responsive genes essential for prostate cancer cell proliferation and survival. The continuous formulation maintains sustained androgen receptor antagonism to provide durable suppression of castration-resistant prostate cancer progression.","oneSentence":"Darolutamide is an androgen receptor antagonist that blocks the binding of androgens to the androgen receptor, inhibiting androgen-driven prostate cancer cell growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:40.177Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-metastatic castration-resistant prostate cancer (nmCRPC)"},{"name":"Metastatic castration-resistant prostate cancer (mCRPC)"}]},"trialDetails":[{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT05999968","phase":"PHASE1","title":"Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-01-12","conditions":"Prostatic Neoplasms","enrollment":10},{"nctId":"NCT05849298","phase":"PHASE2","title":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-03","conditions":"Prostatic Neoplasm","enrollment":49},{"nctId":"NCT04104893","phase":"PHASE2","title":"A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2020-02-20","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":40},{"nctId":"NCT07268794","phase":"PHASE2","title":"CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-11-30","conditions":"Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":112},{"nctId":"NCT06594926","phase":"PHASE2","title":"Working Out M0 Bipolar Androgen Therapy","status":"RECRUITING","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","startDate":"2024-08-14","conditions":"Prostate Cancer","enrollment":69},{"nctId":"NCT04464226","phase":"PHASE3","title":"Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer","status":"RECRUITING","sponsor":"Bayer","startDate":"2020-10-20","conditions":"Cancer","enrollment":402},{"nctId":"NCT05346848","phase":"PHASE2","title":"Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer","status":"RECRUITING","sponsor":"Institut Bergonié","startDate":"2023-02-24","conditions":"Prostate Cancer","enrollment":62},{"nctId":"NCT06320067","phase":"PHASE3","title":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-06-11","conditions":"Prostate Cancer Metastatic","enrollment":3360},{"nctId":"NCT05974774","phase":"PHASE3","title":"Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-05-23","conditions":"Prostate Cancer","enrollment":1600},{"nctId":"NCT02972060","phase":"PHASE2","title":"ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-12-01","conditions":"Prostate Cancer","enrollment":61},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT05413421","phase":"PHASE1","title":"Study of ORIC-944 in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"ORIC Pharmaceuticals","startDate":"2022-06-01","conditions":"Metastatic Prostate Cancer","enrollment":250},{"nctId":"NCT03903835","phase":"PHASE3","title":"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2019-02-01","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":750},{"nctId":"NCT06306612","phase":"NA","title":"CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-03-21","conditions":"Prostate Cancer","enrollment":192},{"nctId":"NCT06496581","phase":"PHASE3","title":"Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-09-12","conditions":"Prostate Cancer Metastatic","enrollment":500},{"nctId":"NCT06276465","phase":"PHASE3","title":"Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-10-07","conditions":"Prostatic Cancer, Castration-Resistant","enrollment":336},{"nctId":"NCT03724747","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-12-18","conditions":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":63},{"nctId":"NCT06585007","phase":"PHASE3","title":"Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2023-12-19","conditions":"Castration-resistant Prostate Cancer, Oligoprogressive","enrollment":246},{"nctId":"NCT06575257","phase":"PHASE2","title":"Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-05-01","conditions":"Prostate Cancer","enrollment":80},{"nctId":"NCT02933801","phase":"PHASE2","title":"ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2017-03-31","conditions":"Prostate Cancer Metastatic, Prostate Cancer","enrollment":92},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT06177015","phase":"PHASE3","title":"Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-12-11","conditions":"Metastatic Prostate Cancer, Intermitent Anti-androgen Therapy","enrollment":200},{"nctId":"NCT05771896","phase":"PHASE3","title":"Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC","status":"WITHDRAWN","sponsor":"GenesisCare USA","startDate":"2023-09","conditions":"Metastatic Prostate Cancer","enrollment":""},{"nctId":"NCT05249712","phase":"PHASE2","title":"Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-01-01","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT04237584","phase":"PHASE3","title":"A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients","status":"TERMINATED","sponsor":"MANA RBM","startDate":"2020-06-30","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Darolutamide"],"phase":"phase_3","status":"active","brandName":"Darolutamide continuous","genericName":"Darolutamide continuous","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Darolutamide is an androgen receptor antagonist that blocks the binding of androgens to the androgen receptor, inhibiting androgen-driven prostate cancer cell growth. Used for Non-metastatic castration-resistant prostate cancer (nmCRPC), Metastatic castration-resistant prostate cancer (mCRPC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}